TreatmentTrends®: Breast Cancer Q2 2015 (US) in the first in a series of reports that examine current trends in the management of advanced/metastatic breast cancer from the perspective of medical oncologists. TreatmentTrends® are syndicated reports that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® reports evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Assess current and anticipated use of hormone therapy, chemotherapy and targeted therapy among advanced/metastatic breast cancer patients. How does prescribing of currently available therapies differ by hormone receptor (HR) and human epidermal growth factor receptor (HER2) status and by line of therapy? How is prescribing anticipated to change over the next six months?

  • Assess how the importance and performance of various attributes (e.g., efficacy, safety, dosing) differ between products. For example, how important an attribute is improvement in quality of life according to surveyed medical oncologists? How do products available today, such as Roche/Genentech/Chugai’s Herceptin, perform on this attribute? What hidden opportunities are available for drug manufacturers?

  • Assess sales representative contact frequency, sales representative performance, and physician message recall between products. How many times, on average, in the past six months has a sales representative visited physicians for the various current therapies? What percentages of physicians were visited in the past month, and what messages were recalled by brand?

  • Understand medical oncologists’ perception of late-stage breast cancer therapies, including awareness of and familiarity with products in late-stage development. The report covers approximately 15 products in late-stage development. What are surveyed physician’s most desired attributes for future advanced/metastatic breast cancer therapies? How do surveyed oncologists’ rank future breast cancer treatments (including the PI3K inhibitors, the PARP inhibitors, HDAC inhibitors and vaccines)?


Markets covered: United States.

Primary research: 99 medical oncologists.

Indication coverage: Advanced/metastatic breast cancer.

Author(s): Amy Duval, M.Res.

Related Reports

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4

View Details

Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...

View Details

Breast Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key breast cancer patient popu...

View Details